Lexicon Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Lexicon Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- LXRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001062822
Board of directors
-
Administratiekantoor Westend Stichting · DirectorSince 2023
-
Alan S. Nies · DirectorSince 2023
-
Amaury Wittouck · DirectorSince 2023
-
Christopher J. Sobecki · DirectorSince 2023
-
Diane E. Sullivan · DirectorSince 2023
-
Frank Palantoni · DirectorSince 2023
-
International S.c.a. Artal · DirectorSince 2023
-
Ivan Cheung · DirectorSince 2024
-
Judith L. Swain · DirectorSince 2023
-
Lonnel Coats · Director · Chief Executive OfficerSince 2023
-
Michael Exton · Director · Chief Executive OfficerSince 2024
-
Participations S.a R.l. Artal · DirectorSince 2024
-
Philippe Amouyal · DirectorSince 2023
-
Raymond Debbane · DirectorSince 2023
-
Robert J. Lefkowitz M.D. · DirectorSince 2023
-
S.a. Westend · DirectorSince 2023
-
Sam L. Barker · DirectorSince 2023
Chief executives
Michael Exton
· Chief Executive Officer
Since July 2024
Lonnel Coats
· Chief Executive Officer
Until July 2024
· Former
Board connections
10 of this board's directors also sit on 4 other boards.
- via Administratiekantoor Westend Stichting, Amaury Wittouck, International S.c.a. Artal, Participations S.a R.l. Artal, Philippe Amouyal and S.a. Westend
- via Christopher J. Sobecki and Raymond Debbane
- via Diane E. Sullivan
- via Sam L. Barker
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 10, 2024 | Artal Group S.A. Director, 10% owner | Option exercise | +57,546,100 | — | — |
| Apr 28, 2024 | Judith L. Swain Director | Option exercise | +8,032 | — | — |
| Apr 28, 2024 | Christopher J. Sobecki Director | Option exercise | +8,032 | — | — |
| Apr 28, 2024 | Robert J. Lefkowitz M.D. Director | Option exercise | +8,032 | — | — |
| Apr 28, 2024 | Raymond Debbane Director | Option exercise | +8,032 | — | — |
| Apr 28, 2024 | Sam L. Barker Director | Option exercise | +8,032 | — | — |
| Apr 28, 2024 | Philippe Amouyal Director | Option exercise | +8,032 | — | — |
| Mar 13, 2024 | Administratiekantoor Westend Stichting Director, 10% owner | Grant or award | +1,150,922 | $108.50 | $124,875,037 |
| Feb 28, 2024 | Alexander Kristen Officer (VP, Finance and Accounting) | Option exercise | +2,700 | — | — |
| Feb 28, 2024 | WADE JEFFREY L Officer (President and CFO) | Option exercise | +11,177 | — | — |
| Feb 28, 2024 | McDermott Wendy Officer (VP, Human Resources) | Option exercise | +18,944 | — | — |
| Feb 28, 2024 | MAIN ALAN J Officer (EVP, Innov & Chem Sciences) | Option exercise | +8,977 | — | — |
| Feb 28, 2024 | Kassler-Taub Kenneth B. Officer (SVP, Regulatory & QA) | Option exercise | +7,087 | — | — |
| Feb 28, 2024 | Granowitz Craig B Officer (SVP, Chief Medical Officer) | Option exercise | +27,916 | — | — |
| Feb 28, 2024 | Crum Brian T Officer (SVP, General Counsel & Secr.) | Option exercise | +8,750 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.